Unfortunately, in the 29 patients enrolled, the 18.5-month PFS was 58% with increased toxicity confirming posttransplant PD-1 blockade does not improve therapeutic benefit in unselected DLBCL patients. Here, PDCD1 is linked to diffuse large B-cell lymphoma.